Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06343311 · ClinicalTrials.gov registry record · Phase 1

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by Estrella Biopharma.

Recruiting
Registry status
Phase 1
Development phase
21
Enrollment target
2
Study locations

NCT06343311 is a Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Estrella Biopharma. The registered enrollment target is 21 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06343311, a Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Estrella Biopharma.

RECRUITING
Registry status
Phase 1
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Conditions Studied

Lymphoma Non-Hodgkin Lymphoma Non-Hodgkin's Lymphoma Large B-cell Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Lymphoma, Non-Hodgkins Lymphoma, Non-Hodgkin's, Adult Lymphomas Non-Hodgkin's B-Cell B-Cell Non-Hodgkin's Lymphoma (NHL)

Interventions

  • BIOLOGICAL EB103

Study Locations (2)

California

  • University of California, Davis - Sacramento

Texas

  • Baylor Scott & White Research Institute, Texas Oncology - Dallas

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2024-06-01
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

Estrella Biopharma

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06343311

The ClinicalTrials.gov registry entry for NCT06343311 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is Estrella Biopharma, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which EB103 is the first listed.

NCT06343311 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT06343311 about?

NCT06343311 is a clinical study titled "T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)". This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will inclu...

What is the current status of trial NCT06343311?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2024-06-01. Estimated completion is 2027-12-31.

What conditions does trial NCT06343311 study?

This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma.

What interventions are being tested in trial NCT06343311?

The interventions under investigation include: EB103 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06343311?

This trial is sponsored by Estrella Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06343311 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Non-Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.